Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASA404 plus docetaxel versus placebo plus docetaxel in second-line advanced non-small cell lung cancer
NL-OMON33036Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vadimezan and docetaxel in non-small cell lung cancer (NSCLC), sponsored by Novartis. Primary endpoint: overall survival. Started Jun 2009; status: active, not recruiting.
02
Drugs
vadimezandocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON33036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33036.